Organon & Co. (NYSE:OGN) Stock Price Up 5.7% – Still a Buy?

Organon & Co. (NYSE:OGN) shares traded up 5.7% on Tuesday . The company traded as high as $15.95 and last traded at $15.95. 1,984,320 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 2,811,156 shares. The stock had previously closed at $15.08.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays reduced their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Morgan Stanley dropped their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Stock Performance

The business’s fifty day moving average is $15.37 and its two-hundred day moving average is $17.22. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $4.11 billion, a PE ratio of 4.79, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.02%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Institutional Trading of Organon & Co.

A number of hedge funds and other institutional investors have recently modified their holdings of OGN. Sippican Capital Advisors lifted its stake in Organon & Co. by 4.3% in the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after purchasing an additional 627 shares in the last quarter. Commerce Bank grew its holdings in Organon & Co. by 5.5% during the 3rd quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after purchasing an additional 637 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after acquiring an additional 672 shares during the period. Treasurer of the State of North Carolina lifted its position in shares of Organon & Co. by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company’s stock worth $1,688,000 after purchasing an additional 710 shares during the last quarter. Finally, Beam Wealth Advisors Inc. boosted its stake in shares of Organon & Co. by 3.9% during the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock valued at $282,000 after purchasing an additional 717 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.